Medically reviewed on September 13, 2017.
Applies to the following strengths: 8 mg/mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Gout
8 mg via IV infusion every 2 weeks; infuse over no less than 120 minutes via gravity feed, syringe-type pump, or infusion pump
-Patients should receive premedications (e.g., antihistamines, corticosteroids) to minimize the risk of anaphylaxis and infusion reactions.
Use: For the treatment of chronic gout in patients who are refractory to conventional therapy (e.g., patients who have failed to normalize serum uric acid and whose signs/symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated)
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
Data not available
Due to risk of anaphylaxis and infusion reactions:
-Premedicate patients with antihistamines and corticosteroids prior to each infusion.
-The risk of anaphylaxis and infusion reactions is higher in patients who have lost therapeutic response, therefore, monitor serum uric acid levels prior to each infusion.
-Consider discontinuing treatment if levels are greater than 6 mg/dL, especially if 2 consecutive levels exceed 6 mg/dL.
-The safety and efficacy of retreatment with this drug after stopping treatment for more than 4 weeks is unknown. If this drug is restarted after a drug-free interval, patients may be at an increased risk of anaphylaxis and infusion reactions and should be monitored carefully.
US BOXED WARNINGS:
ANAPHYLAXIS AND INFUSION REACTIONS:
-Anaphylaxis and infusion reactions have been reported to occur during and after administration of this drug.
-Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported.
-This drug should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions.
-Patients should be premedicated with antihistamines and corticosteroids.
-Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration.
-Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.
GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA:
-Screen patients at risk for G6PD deficiency prior to starting this drug.
-Hemolysis and methemoglobinemia have been reported with this drug in patients with G6PD deficiency.
-Do not administer this drug to patients with G6PD deficiency.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-This drug should be administered in a healthcare setting by healthcare providers prepared to manage anaphylaxis and infusion reactions.
-Patients should be premedicated with antihistamines and corticosteroids to minimize the risk of anaphylaxis and infusion reactions.
-Administer via IV infusion over no less than 120 minutes; do not give as an IV push or bolus
-If an infusion reaction occurs, the infusion should be slowed or stopped and restarted at a slower rate.
Prior to dilution: Store in carton, protect from light, keep under refrigeration (2C to 8C [36F to 46F]) at all times; do not shake or freeze.
-Store diluted solutions under refrigeration (2C to 8C [36F to 46F]); protect from light; use within 4 hours of dilution.
-Allow diluted solutions to reach room temperature prior to administration; do not subject vial or diluted solution to artificial heating (e.g. hot water, microwave).
-Visually inspect for particulate matter and discoloration; discard if present.
-Withdraw 1 mL (8 mg) of pegloticase (uricase protein) from vial and inject into 250 mL bag of NS or 0.45% NS.
-Invert infusion bag gently to ensure thorough mixing; do not shake.
-Following dilution in infusion bag: Stable for 4 hours at 2C to 8C (36F to 46F) and at room temperature 20C to 25C (68F to 77F); if storage is necessary, preferred storage is refrigeration.
-Do not mix or dilute with other drugs.
-Prior to initiating therapy, patients should discontinue oral urate-lowering medications and not restart on these agents while receiving this drug.
-Patients should receive gout flare prophylaxis starting at least 1 week before initiating therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.
-The risk of anaphylaxis and infusion reactions is higher in patients who have lost therapeutic response, therefore, monitor serum uric acid levels prior to each infusion and consider discontinuing treatment if levels are greater than 6 mg/dL, especially if 2 consecutive levels exceed 6 mg/dL.
-The optimal treatment duration with this drug is unknown.
-Limitation of Use: This drug is not recommended for the treatment of asymptomatic hyperuricemia.
-Hematologic: Screening for G6PD deficiency before starting therapy, especially those at high-risk for G6PD (e.g. patients of African or Mediterranean ancestry).
-Hypersensitivity: Anaphylaxis reactions during infusion; monitor for hypersensitivity reactions after administration
-Local: Infusion reactions during infusion
-Metabolic: serum uric acid levels prior to each infusion
-Inform patients of the risk of serious hypersensitivity reactions and infusion reactions and explain to patients the importance of adhering to their treatment plan to help prevent or lessen the severity of these reactions.
-Patients should be aware of the most common signs and symptoms of hypersensitivity and infusion reactions and should be instructed to report these symptoms promptly should they occur during or after an infusion.
-Patients should understand that gout flares may increase when starting therapy and they should not stop this medication if they experience a flare.
-Patients should be told to immediately seek medical treatment if hypersensitivity reactions occur after an infusion.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about pegloticase
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 6 Reviews – Add your own review/rating
- Drug class: antihyperuricemic agents
Other brands: Krystexxa